Arsanis prices $40M IPO for infectious disease work
Arsanis, a New Hampshire biotech co-founded by Adimab’s Tillman Gerngross, has priced its IPO lower than originally expected, bumping the expected total raise down to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
